- $9.73bn
- $11.32bn
- $2.97bn
- 80
- 34
- 67
- 63
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,595 | 2,537 | 2,810 | 2,791 | 2,974 |
Cost of Revenue | |||||
Gross Profit | 1,492 | 1,325 | 1,550 | 1,531 | 1,647 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2,177 | 2,114 | 2,194 | 2,292 | 2,468 |
Operating Profit | 418 | 423 | 615 | 499 | 506 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 340 | 358 | 559 | 446 | 434 |
Provision for Income Taxes | |||||
Net Income After Taxes | 462 | 336 | 485 | 363 | 358 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 461 | 335 | 485 | 363 | 356 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 461 | 335 | 485 | 363 | 356 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 10.2 | 8.59 | 9.2 | 7.92 | 8.54 |
Dividends per Share |